XRx-026 (XORLO™) — IND submission
Q4 2026
Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company's regulatory path toward NDA filing for gout program XRx-026Source filing
XRTX biotech catalysts & pipeline
XORTX THERAPEUTICS INC · Data as of 2026-10-25